Kingspan Insulated Panels North America Announces Grand Opening of New Facility in Mattoon, Illinois
The Mattoon facility will produce the K-Roc HF Series, which is recognized for its superior fire protection due to its mineral fiber insulation core. The K-Roc HF Series, available in 4-inch, 6-inch, and 8-inch thicknesses, offers up to a two-hour fire rating in wall applications and three-hour fire rating in ceiling applications. The series is available in five profiles, with both embossed and non-embossed finishes, ensuring versatility for a wide range of aesthetic needs.
The K-Roc mineral fiber insulation has the fire ratings required for occupant safety and asset protection in high-value applications like EV battery factories. Historically, K-Roc products have been manufactured exclusively at Kingspan's Langley, British Columbia, Canada site. The Mattoon facility gives Kingspan a new strategic location to meet the increased demand for K-Roc products in facilities across the Midwest, West, Northeast and Southeast.
'We are thrilled to officially open the doors of our new facility in Mattoon,' said Alswinn Kieboom, president of Kingspan Insulated Panels North America. 'This plant is a testament to our continued growth and our passion to deliver exceptional service to our customers. The Mattoon location complements our manufacturing footprint giving us full coverage across Canada and the U.S. with the entire product line.'
In addition to meeting the growing demand, the Mattoon site is also a key part of Kingspan's sustainability strategy through its global Planet Passionate initiative and will undergo a significant number of eco-friendly upgrades. Plans call for solar roof panels, energy-efficient LED lighting, electric vehicle charging stations, a rainwater harvesting system, and a robust recycling program designed to help the company reach its zero waste to landfill goal.
The new Mattoon location is expected to bring approximately 50 new jobs to the region, creating a positive impact on the local economy and furthering Kingspan's commitment to sustainability and innovation.
For facility photos and photos from the grand opening ceremony, click here .
For more information on Kingspan Insulated Panels North America, visit www.kingspanpanels.us .
About Kingspan Insulated Panels – North America
Kingspan Insulated Panels – North America is a business unit of Kingspan, a global company operating in more than 80 countries, with over 250 manufacturing facilities. Kingspan Insulated Panels – North America manufactures and markets three groups of products at its U.S., Canadian and Mexican facilities: insulated metal wall and roof panel systems for commercial/industrial construction; insulated architectural panels for design-driven projects; and controlled environment panels and doors for cold-storage and climate-controlled warehousing. In addition to its commitment to quality and innovation, the company is on the leading edge of the sustainability movement, offering best-of-class products produced in state-of-the-art, eco-friendly facilities. To learn more visit www.kingspanpanels.us
Media ContactBrianna KoenigUproar by Moburst for Kingspan Insulated Panels North America
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
iSpecimen Inc. Announces Closing of Approximately $1.75 Million Private Placement Priced At-the-Market
By GlobeNewswire Published on August 5, 2025, 03:45 IST WOBURN, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) ('iSpecimen' or the 'Company'), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it closed its previously announced private placement pursuant to a securities purchase agreement with accredited investors for aggregate gross proceeds of approximately $1.75 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to pay $500,000 for marketing and advertising services to be provided by IR Agency LLC, and the remainder for working capital and general corporate purposes. In connection with the offering, the Company issued 1,559,828 shares of common stock (or pre-funded warrants to purchase shares of common stock) at a purchase price of $1.122 per share, priced at-the-market under Nasdaq rules. The offering closed on August 4, 2025. WestPark Capital, Inc. acted as the exclusive placement agent in connection with the offering. Additional details regarding the offering will be available in a Form 8-K to be filed by the Company with the Securities and Exchange Commission (the 'SEC'). The securities described above have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About iSpecimen iSpecimen (Nasdaq: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit . Safe Harbor Statement Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' These statements include, but are not limited to, statements concerning the development of our company. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including the uncertainty regarding future commercial success; risks and uncertainties associated with market conditions and the Company's ability to satisfy the closing conditions related to the Offering. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on April 14, 2025, as well as other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, iSpecimen specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
2 hours ago
- Yahoo
Tesla's Regulatory Credit Cash Cow Is Fading Fast: Why it Matters
For years, Tesla TSLA has made big money not just from selling electric vehicles (EVs), but also from selling regulatory credits to other automakers. These credits have aided Tesla's overall margins, even when car sales were under pressure. But that extra boost is shrinking fast now. And if the trend continues, it could just worsen things for the company. Tesla has been selling billions of dollars' worth of regulatory credits to legacy automakers who needed them to offset their gas-guzzling vehicle fleets and avoid fines. The revenues—more than $10.6 billion since 2019—have been a critical boost to Tesla's profits, especially during times when the core business struggled to stay in the black. In Q2'25, Tesla reported $439 million in regulatory credit revenues. On the surface, that still looks solid. But the trend tells a different story. Credit sales have fallen sharply from $890 million in Q2'24, marking a nearly 50% drop in just a year. And it's not a blip—it's a steady slide. From $739 million in Q3'24 to $692 million in Q4'24, then $595 million in Q1'25—and now $439 million. Policy Shifts and EV Competition Add Pressure Last month, President Trump's tax and spending bill officially scrapped the penalties for automakers failing to meet Corporate Average Fuel Economy (CAFE) standards. That's a game-changer. Automakers who previously bought credits from Tesla to avoid hefty fines—over $1.1 billion worth from 2011 to 2020—now have no reason to do so. The penalty is effectively gone. That removes the key incentive behind Tesla's regulatory credit windfall. And it couldn't come at a worse time. Tesla is already facing a slump in deliveries and profits. The company recently posted two straight quarters of delivery declines. Without credit sales to somewhat plug the gap, Tesla's core business will face more pressure. Some automakers may still have long-term credit purchase agreements with Tesla, but those contracts may be renegotiated—or even canceled—early. In fact, the credit revenues could disappear by next year. And it's not just the policy shift. Many legacy automakers like General Motors GM, Ford F and Stellantis STLA are also shifting their gears to electric. As they scale up their EV output and reduce emissions, they need fewer regulatory credits. A Fading Lifeline Tesla Can't Ignore While headlines are busy tracking CEO Elon Musk's political battles or the loss of $7,500 EV buyer tax credits, this regulatory credit risk of Tesla has not gotten much attention. But the risk is real—and growing. Regulatory credits have quietly propped up Tesla's profits for years. But the safety net could be vanishing. Unless Tesla can make up for the loss with stronger sales, tighter cost controls or big wins in robotaxis, the road ahead could get bumpier. The Zacks Rundown for Tesla Shares of Tesla have lost around 20% over the past six months compared with the industry's decline of 17%. Meanwhile, shares of Ford and General Motors are up 8% and 10%, respectively, while Stellantis is down 32% during the same timeframe. Image Source: Zacks Investment Research From a valuation standpoint, TSLA trades at a forward price-to-sales ratio of 9.5, way above the industry. It carries a Value Score of D. Meanwhile, General Motors trades at a forward sales multiple of 0.28, Ford at 0.27 and Stellantis at 0.14. Image Source: Zacks Investment Research See how the Zacks Consensus Estimate for TSLA's earnings has been revised over the past 90 days. Image Source: Zacks Investment Research Tesla stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ford Motor Company (F) : Free Stock Analysis Report General Motors Company (GM) : Free Stock Analysis Report Tesla, Inc. (TSLA) : Free Stock Analysis Report Stellantis N.V. (STLA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
2 hours ago
- Yahoo
Should You Buy Lucid Group (LCID) Stock Before Aug. 5? Here's What History Says
Key Points Lucid Group has already reported vehicle production and delivery numbers for the second quarter, but will publish full Q2 results on Aug. 5. The company has historically seen big sell-offs following its earnings reports. Past performance can't predict what will happen to Lucid stock after earnings, but its share price could make a big move. 10 stocks we like better than Lucid Group › Lucid Group (NASDAQ: LCID) stock saw a big pop last month after the company announced that it had entered into a robotaxi partnership with Uber Technologies. Uber will purchase 20,000 or more of the automaker's vehicles over the next six years and use them as key components of its robotaxi fleet. Lucid's share price has since had a substantial pullback. There will soon be another big potential catalyst that could spur substantial moves for the stock. The electric-vehicle (EV) specialist is set to release its second-quarter report and host an earnings conference call after the market closes on Aug. 5, and investors will be taking a close look at its margins and bottom line. If you're wondering what history says about your chances of success with buying Lucid's stock ahead of earnings, take a look at the chart below and read on for a deeper look at dynamics that could shape the company's valuation. Lucid's stock has historically struggled after earnings As the chart above shows, it's historically been a bad move to buy Lucid's shares ahead of the company's earnings reports. Most of its quarterly releases have corresponded with big sell-offs for the stock, and the EV specialist's share price is now down roughly 87% over the last three years. Sales and earnings performances have generally come in below the levels needed to spur gains for the stock: Lucid has posted large losses across its history as a publicly traded company. At the same time, the business's sales growth has been very uneven after an initial ramp-up period. Heading into the upcoming earnings report, the business has recorded a net loss of roughly $2.4 billion on sales of roughly $870 million across the trailing-12-month (TTM) period. In other words, Lucid has lost roughly $2.76 for every $1 in revenue that it's generated over that stretch. There are good reasons to think that losses will continue to come in at high levels for the foreseeable future. Will Lucid stock see another sell-off after the Q2 report? Because Lucid announces its vehicle production and delivery numbers after each quarter, investors already have some key insights into what to expect with the second-quarter report. In the update it published at the beginning of July, the company announced that it had produced 3,863 vehicles and delivered 3,309 vehicles in Q2. For comparison, it produced 2,110 vehicles and delivered 2,394 vehicles in last year's second quarter. The rollout of the Gravity SUV has helped spur a significant uptick in production and deliveries, but the stock could see a big pullback if the upcoming Q2 report arrives with a wider-than-expected loss. Lucid's path to profitability hinges on achieving economies of scale that allow it to shift into posting positive gross margins on each vehicle sold, and then continuing on that track until it can deliver positive operating income margins. As things stand, it currently costs the company far more to produce each one of its vehicles than is recouped through a sale. Historically, Lucid Group's earnings reports have arrived with wide losses that have driven sell-offs for the stock. Given that shares already trade at a severely beaten-down price compared to where they were a few years ago, there's no guarantee that this dynamic will play out again after the next earnings report -- but investors will likely be looking to see that Lucid has a feasible path to eventually delivering big margin improvements. Should you invest $1,000 in Lucid Group right now? Before you buy stock in Lucid Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Noonan has positions in Uber Technologies. The Motley Fool has positions in and recommends Uber Technologies. The Motley Fool has a disclosure policy. Should You Buy Lucid Group (LCID) Stock Before Aug. 5? Here's What History Says was originally published by The Motley Fool Sign in to access your portfolio
